Patents by Inventor Ivan Lieberburg

Ivan Lieberburg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating inflammatory and autoimmune diseases with natalizumab
    Patent number: 11292845
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: April 5, 2022
    Assignee: Biogen MA Inc.
    Inventor: Ivan Lieberburg
  • METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
    Publication number: 20190315871
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
    Type: Application
    Filed: March 18, 2019
    Publication date: October 17, 2019
    Inventor: Ivan Lieberburg
  • Methods of treating inflammatory and autoimmune diseases with natalizumab
    Patent number: 10233245
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: March 19, 2019
    Assignee: BIOGEN MA INC.
    Inventor: Ivan Lieberburg
  • METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
    Publication number: 20170247457
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
    Type: Application
    Filed: May 16, 2017
    Publication date: August 31, 2017
    Inventor: Ivan Lieberburg
  • Immunotherapy regimes dependent on ApoE status
    Patent number: 9644025
    Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: May 9, 2017
    Assignees: WYETH LLC, JANSSEN SCIENCES IRELAND UC
    Inventors: Ronald Black, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Jack Steven Jacobsen, Davinder Gill, Lioudmila Tchistiakova, Angela Widom
  • METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
    Publication number: 20170022276
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
    Type: Application
    Filed: October 4, 2016
    Publication date: January 26, 2017
    Inventor: Ivan Lieberburg
  • Methods of treating inflammatory and autoimmune diseases with natalizumab
    Patent number: 9493567
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: November 15, 2016
    Assignee: Biogen Inc.
    Inventor: Ivan Lieberburg
  • Use of tau to monitor immunotherapy
    Patent number: 9272030
    Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: March 1, 2016
    Assignees: JANSSEN SCIENCES IRELAND UC, WYETH LLC
    Inventors: Ronald Black, Jack Steven Jacobsen, Lioudmila Tchistiakova, Angela Widom, Davinder Gill, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Wagner Zago, Manuel J. Buttini, Gene G. Kinney
  • USE OF TAU TO MONITOR IMMUNOTHERAPY
    Publication number: 20150118223
    Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.
    Type: Application
    Filed: April 22, 2011
    Publication date: April 30, 2015
    Applicants: WYETH LLC, JANSSEN ALZHEIMER IMMUNOTHERAPY
    Inventors: Ronald Black, Jack Steven Jacobsen, Lioudmila Tchistiakova, Angela Widom, Davinder Gill, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Wagner Zago, Manuel J. Buttini, Gene G. Kinney
  • STEROID SPARING AGENTS AND METHODS OF USING SAME
    Publication number: 20150056205
    Abstract: This invention relates generally to methods of treating inflammatory bowel diseases (IBD), asthma, Crohn's Disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid-sparing effective amount of an immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.
    Type: Application
    Filed: July 28, 2014
    Publication date: February 26, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Ivan LIEBERBURG
  • Treatment of amyloidogenic diseases
    Patent number: 8784810
    Abstract: The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A?. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: July 22, 2014
    Assignees: Janssen Alzheimer Immunotherapy, Wyeth LLC
    Inventors: Ivan Lieberburg, James Callaway, Michael Grundman
  • Treatment of amyloidogenic diseases
    Patent number: 8613920
    Abstract: The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A?. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: December 24, 2013
    Assignees: Janssen Alzheimer Immunotherapy, Wyeth LLC
    Inventors: Ivan Lieberburg, James Callaway, Michael Grundman
  • USE OF TAU TO MONITOR IMMUNOTHERAPY
    Publication number: 20130209453
    Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.
    Type: Application
    Filed: April 22, 2011
    Publication date: August 15, 2013
    Applicants: WYETH LLC, JANSSEN ALZHEIMER IMMUNOTHERAPY
    Inventors: Ronald Black, Jack Steven Jacobsen, Lioudmila Tchistiakova, Angela Widom, Davinder Gill, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Wagner Zago, Manuel J. Buttini
  • Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
    Patent number: 8410115
    Abstract: Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment. Monitoring for the JC virus and educating caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of alpha 4 inhibitor therapy.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: April 2, 2013
    Assignee: Elan Pharmaceuticals, Inc.
    Inventor: Ivan Lieberburg
  • Methods and compositions for treating liquid tumors
    Patent number: 8269009
    Abstract: The application relates to a method of using compositions having anti-alpha-4 integrin and/or anti-alpha-9 integrin activity to inhibit liquid tumor growth, malignancies thereof and/or development of metastases thereof that involve expression of an alpha-4 integrin and/or alpha-9 integrin. Pharmaceutical compositions and combination therapies (for example, with chemotherapies) for the inhibition of liquid tumor growth, malignancies thereof and/or development of metastases thereof are also provided.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: September 18, 2012
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Elizabeth Messersmith, Ivan Lieberburg
  • IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS
    Publication number: 20120070379
    Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.
    Type: Application
    Filed: September 13, 2011
    Publication date: March 22, 2012
    Applicants: Janssen Alzheimer Immunotherapy, Wyeth LLC
    Inventors: Ronald Black, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Jack Steven Jacobsen, Davinder Gill, Lioudmila Tchistiakova, Angela Widom
  • TREATMENT OF AMYLOIDOGENIC DISEASES
    Publication number: 20110229413
    Abstract: The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A?. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.
    Type: Application
    Filed: October 17, 2008
    Publication date: September 22, 2011
    Applicants: JANSSEN ALZHEIMER IMMUNOTHERAPY, WYETH LLC
    Inventors: Ivan Lieberburg, James Callaway, Michael Grundman
  • IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS
    Publication number: 20100266505
    Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.
    Type: Application
    Filed: October 17, 2008
    Publication date: October 21, 2010
    Applicants: Wyeth LLC, Janssen Alzheimer Immunotherapy
    Inventors: Ronald Black, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Jack Steven Jacobsen, Davinder Gill, Lioudmila Tchistiakova, Angela Widom
  • TREATMENT OF AMYLOIDOGENIC DISEASES
    Publication number: 20100221187
    Abstract: The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A?. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.
    Type: Application
    Filed: July 27, 2007
    Publication date: September 2, 2010
    Applicants: Janssen Alzheimer Immunotherapy, Wyeth LLC
    Inventors: Ivan Lieberburg, James Callaway, Michael Grundman
  • Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab
    Publication number: 20100196318
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease; and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
    Type: Application
    Filed: April 9, 2010
    Publication date: August 5, 2010
    Inventor: Ivan Lieberburg